Literature DB >> 22349173

[Treatment strategies for asthma].

S Korn1, C Taube, R Buhl.   

Abstract

Asthma is characterized by variable and reversible airflow limitation and bronchial hyperresponsiveness due to chronic airway inflammation. Asthma treatment is based on the patients' asthma control status. Central to treatment recommendations is anti-inflammatory therapy with inhaled corticosteroids plus a rapid-acting β(2)-agonist as required. If this is not sufficient to achieve at least partial asthma control, the dose of the inhaled corticosteroid should be increased and a long-acting β(2)-agonist should be added. Other controllers, such as leukotriene antagonists or slow-release theophylline are alternative or additive options. Systemic treatment with corticosteroids and/or the monoclonal anti-IgE antibody omalizumab are reserved for patients with severe asthma. Strategies aimed at preventing airway irritation, reducing exposure to exogenous allergens and inhaled irritants as well as asthma education are other key elements of asthma management.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22349173     DOI: 10.1007/s00108-011-3001-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  14 in total

Review 1.  Asthma.

Authors:  Christopher H Fanta
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

Review 2.  Influence of comorbid conditions on asthma.

Authors:  L-P Boulet
Journal:  Eur Respir J       Date:  2009-04       Impact factor: 16.671

3.  Lebrikizumab treatment in adults with asthma.

Authors:  Jonathan Corren; Robert F Lemanske; Nicola A Hanania; Phillip E Korenblat; Merdad V Parsey; Joseph R Arron; Jeffrey M Harris; Heleen Scheerens; Lawren C Wu; Zheng Su; Sofia Mosesova; Mark D Eisner; Sean P Bohen; John G Matthews
Journal:  N Engl J Med       Date:  2011-08-03       Impact factor: 91.245

Review 4.  Anti-IgE antibodies for the treatment of asthma.

Authors:  Roland Buhl
Journal:  Curr Opin Pulm Med       Date:  2005-01       Impact factor: 3.155

Review 5.  Inhaled glucocorticoids for asthma.

Authors:  P J Barnes
Journal:  N Engl J Med       Date:  1995-03-30       Impact factor: 91.245

6.  Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

Authors:  M Humbert; R Beasley; J Ayres; R Slavin; J Hébert; J Bousquet; K-M Beeh; S Ramos; G W Canonica; S Hedgecock; H Fox; M Blogg; K Surrey
Journal:  Allergy       Date:  2005-03       Impact factor: 13.146

7.  The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.

Authors:  J Bousquet; P Cabrera; N Berkman; R Buhl; S Holgate; S Wenzel; H Fox; S Hedgecock; M Blogg; G Della Cioppa
Journal:  Allergy       Date:  2005-03       Impact factor: 13.146

8.  Global strategy for asthma management and prevention: GINA executive summary.

Authors:  E D Bateman; S S Hurd; P J Barnes; J Bousquet; J M Drazen; J M FitzGerald; P Gibson; K Ohta; P O'Byrne; S E Pedersen; E Pizzichini; S D Sullivan; S E Wenzel; H J Zar
Journal:  Eur Respir J       Date:  2008-01       Impact factor: 16.671

9.  Mepolizumab and exacerbations of refractory eosinophilic asthma.

Authors:  Pranabashis Haldar; Christopher E Brightling; Beverley Hargadon; Sumit Gupta; William Monteiro; Ana Sousa; Richard P Marshall; Peter Bradding; Ruth H Green; Andrew J Wardlaw; Ian D Pavord
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

10.  Development of the asthma control test: a survey for assessing asthma control.

Authors:  Robert A Nathan; Christine A Sorkness; Mark Kosinski; Michael Schatz; James T Li; Philip Marcus; John J Murray; Trudy B Pendergraft
Journal:  J Allergy Clin Immunol       Date:  2004-01       Impact factor: 10.793

View more
  1 in total

Review 1.  Bronchial asthma: is personalized therapy on the horizon?

Authors:  Christian Taube
Journal:  Allergo J Int       Date:  2014-11-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.